PRESENTED AT ACC AND PUBLISHED IN JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY, THE CARDIOMEMS™ HF SYSTEM OFFERS SUSTAINED BENEFITS FOR PATIENTS SUFFERING FROM SYMPTOMATIC HEART FAILURE
HEART FAILURE HOSPITALIZATIONS CUT NEARLY IN HALF AND AN AVERAGE REDUCTION OF $10,500 IN COMPREHENSIVE HEALTH CARE COSTS SIX MONTHS FOLLOWING IMPLANT
WASHINGTON, March 19, 2017 /PRNewswire/ -- New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS™ HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure.
The CardioMEMS HF System is the first and only U.S. Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III). The latest research includes more than 1,100 Medicare patients and was presented today during the American College of Cardiology (ACC) 66th Annual Scientific Sessions in Washington, D.C., and simultaneously published in the Journal of the American College of Cardiology (JACC).